WAM
TEVA icon

Wolverine Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Wolverine Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30 Buy
+1
New +$32 ﹤0.01% 1665
2023
Q2 		– Sell
-4,914
Closed -$39.8K – 1929
2023
Q1 		$43.5K Sell
4,914
-400
-8% -$3.96K ﹤0.01% 1222
2022
Q4 		$48.5K Hold
5,314
– – ﹤0.01% 1388
2022
Q3 		$42K Sell
5,314
-89,532
-94% -$792K ﹤0.01% 1638
2022
Q2 		$713K Hold
94,846
– – 0.01% 897
2022
Q1 		$890K Sell
94,846
-30,000
-24% -$250K 0.01% 791
2021
Q4 		$1M Hold
124,846
– – 0.01% 784
2021
Q3 		$1.22M Buy
124,846
+19,900
+19% +$186K 0.01% 663
2021
Q2 		$1.04M Hold
104,946
– – 0.01% 627
2021
Q1 		$1.21M Sell
104,946
-60,000
-36% -$688K 0.01% 573
2020
Q4 		$1.59M Buy
164,946
+30,900
+23% +$296K 0.01% 520
2020
Q3 		$1.21M Buy
134,046
+69,000
+106% +$730K 0.01% 514
2020
Q2 		$802K Sell
65,046
-29,400
-31% -$332K 0.01% 601
2020
Q1 		$848K Buy
94,446
+44,300
+88% +$454K 0.01% 547
2019
Q4 		$491K Buy
50,146
+21,146
+73% +$189K 0.01% 794
2019
Q3 		$199K Hold
29,000
– – ﹤0.01% 1000
2019
Q2 		$267K Buy
+29,000
New +$350K ﹤0.01% 990
2019
Q1 		– Sell
-565,991
Closed -$8.73M – 1689
2018
Q4 		$8.73M Buy
565,991
+174,000
+44% +$3.57M 0.1% 178
2018
Q3 		$8.44M Sell
391,991
-168,928
-30% -$3.92M 0.1% 209
2018
Q2 		$13.6M Buy
560,919
+168,928
+43% +$3.44M 0.18% 122
2018
Q1 		$6.7M Hold
391,991
– – 0.09% 214
2017
Q4 		$7.43M Buy
391,991
+157,850
+67% +$2.37M 0.08% 224
2017
Q3 		$4.12M Buy
234,141
+75,649
+48% +$1.7M 0.05% 292
2017
Q2 		$5.26M Buy
+158,492
New +$4.91M 0.07% 236
2017
Q1 		– Sell
-51,105
Closed -$1.74M – 1381
2016
Q4 		$1.85M Sell
51,105
-47,912
-48% -$1.91M 0.02% 420
2016
Q3 		$4.55M Buy
+99,017
New +$5.17M 0.07% 264
2015
Q4 		– Sell
-55,877
Closed -$3.45M – 1918
2015
Q3 		$3.15M Buy
55,877
+44,235
+380% +$2.87M 0.07% 249
2015
Q2 		$688K Buy
11,642
+11,100
+2,048% +$685K 0.02% 551
2015
Q1 		$33K Buy
+542
New +$31.5K ﹤0.01% 1347
2014
Q4 		– Sell
-13,300
Closed -$741K – 2480
2014
Q3 		$714K Buy
13,300
+10,800
+432% +$572K 0.01% 575
2014
Q2 		$131K Hold
2,500
– – ﹤0.01% 1069
2014
Q1 		$132K Sell
2,500
-24,300
-91% -$1.12M ﹤0.01% 1023
2013
Q4 		$1.07M Buy
26,800
+3,000
+13% +$118K 0.02% 496
2013
Q3 		$899K Buy
23,800
+5,000
+27% +$195K 0.02% 572
2013
Q2 		$736K Buy
+18,800
New +$732K 0.02% 582

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wolverine Asset Management's TEVA Position: Q1 2026 in Review

Wolverine Asset Management opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 1 share worth $30. The stake represents ﹤0.01% of the portfolio and ranks #1665 among its holdings. This is a return to the name: Wolverine Asset Management previously reported a position in TEVA as recently as Q1 2023.

Wolverine Asset Management first reported a position in TEVA in Q2 2013 and has held it in 35 quarters since. The position peaked at $13.6M in Q2 2018. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Wolverine Asset Management held 1 share of Teva Pharmaceuticals worth $30 as of Q1 2026.
  • Teva Pharmaceuticals was a new Wolverine Asset Management position in Q1 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1665 holding.
  • Wolverine Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
  • Wolverine Asset Management's Teva Pharmaceuticals position peaked at $13.6M in Q2 2018.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.